Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Apr 16, 2018
  • Factor XIa inhibitor moving into Phase 2 Trials for Secondary Stroke Prevention
  • Bristol-Myers Squibb to receive upfront payment and companies to share development and commercialization costs, and global profits

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced a worldwide collaboration with Janssen Pharmaceuticals, Inc. (Janssen) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’s Factor XIa (FXIa) inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions. The companies are expected to advance BMS-986177 into Phase 2 clinical trials in the second half of 2018 for the study of secondary stroke prevention.

Thrombotic disorders include cardiovascular conditions such as coronary artery disease, stroke and peripheral artery disease. BMS-986177 is an inhibitor of Factor XIa, and is being explored for its potential to improve upon the standard of care by reducing the risk of vascular events – without increasing the risk of bleeding – in patients with thrombotic disorders.

“At Bristol-Myers Squibb, we are rooted in our commitment to patients with cardiovascular disease. We are proud to partner with Janssen on our shared vision for advancing cutting-edge science to develop potential new treatments such as BMS-986177 for serious cardiovascular disease,” said Tom Lynch, M.D., executive vice president and chief scientific officer, Bristol-Myers Squibb. “By combining the strength of our companies’ extensive expertise in the development and commercialization of cardiovascular treatments, we can maximize the potential of FXIa inhibition.”

Bristol-Myers Squibb has a strong heritage of pioneering research and advancing the development of novel compounds to address areas of high unmet need for patients with serious cardiovascular conditions. The collaboration will leverage both companies’ resources and expertise to establish a broad development program across multiple indications.

Janssen will pay Bristol-Myers Squibb an upfront sum along with potential development and regulatory milestone payments. The companies will share development costs and commercial profits and losses. Additional terms of the agreement were not disclosed.

About Factor XIa

Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway.i It was first noticed as a potential approach to thrombosis because people with little or no FXIa (Hemophilia C) show virtually no untoward bleeding in the absence of a major injury or surgery. Further, a small study of Hemophilia C patients showed a lower risk of stroke. Conversely, elevated levels of FXI /FXIa are a risk factor for stroke and venous thromboembolism.

Preclinical and early clinical studies suggest that selectively inhibiting the intrinsic branch of the coagulation cascade at an upstream protease such as FXIa could be a key strategy to reducing the risk of vascular events without increasing the risk of bleeding.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitter, YouTube and Facebook.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2017 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

____________

i R. Al-Horani, et al. Factor XIa inhibitors: A review of patent literature. Expert Opin Ther Pat. 2016; 26(3): 323-345.

Source: Bristol-Myers Squibb Company

Bristol-Myers Squibb

Media:

Lisa McCormick Lavery, 609-252-7602

lisa.mccormicklavery@bms.com

or

Ken Dominski, 609-252-5251

ken.dominski@bms.com

or

Investors:

Tim Power, 609-252-7509

timothy.power@bms.com

or

Bill Szablewski, 609-252-5894

william.szablewski@bms.com